| The results show that genetic abrogation of Nrf2 impairs the malignant phenotype of K-Ras-transformed cells in vitro and in vivo, and demonstrates the critical role of Nrf2 in promoting cell survival and drug resistance in cells harboring oncogenic K-ras. | None |
| Results show that K-Ras has a more substantial population of state 1 in solution than H-Ras, which predominantly favors state 2. The oncogenic mutant K-RasG12D favors state 2, changing the balance of conformational states in favor of interactions with effector proteins. | None |
| Proscillaridin A as a selective inhibitor of cells harboring the oncogenic KRas(G12V) allele. | None |
| deletion of the oncogenic KRAS allele resulted in enhanced STIM1 expression and greater Ca(2+) influx. | None |
| a central and indispensable role for SHP2 in oncogenic KRAS-driven tumors, is reported. | None |
| Studies on four cellular proto-oncogenes and their expression in PCC4 embryonal carcinoma cells: amplification of c-Ki-ras oncogene. | None |
| That CRISPR-Cas9-mediated genome editing can potentially be used for the treatment of cancer patients, specifically those with oncogenic KRAS mutations. | None |
| Immunohistochemical detection of ras oncogene p21 product in benign and malignant mammary tissue in man. | None |
| Amplification and rearrangement of Ki-ras oncogene in human teratocarcinoma-derived cell lines. | None |
| PIP5K1A loss reduces oncogenic KRAS signaling. | None |
| Characterization of G1 transit induced by the mitogenic-oncogenic viral Ki-ras gene product. | None |
| Functional data indicate that modulating Ras-responsive element-binding protein 1 (RREB1) expression in human DLBCL cell lines in vitro alters KRAS expression, signaling, and proliferation; thus, suggesting that this proto-oncogene is a common mechanism of RAS/MAPK hyperactivation in human DLBCL. | None |
| PNRC1 ablates the enhanced proliferation triggered by established oncogenes such as RAS and MYC These observations uncover a previously undescribed mechanism of tumor suppression, whereby the cytoplasmic decapping machinery is hauled within nucleoli, tightly regulating ribosomal RNA maturation. | None |
| the absence of ATRX increases sensitivity to injury and oncogenic KRAS only in female mice. | None |
| HIC-5 regulates mitochondrial ROS production in tumor cells while requiring activated KRAS to mediate its effect on NOX4 in oncogene-induced senescence and tumor invasiveness. | None |
| Localization of the KRAS2 oncogene in the domestic rabbit (Oryctolagus cuniculus). | None |
| Aberrant expression of the K-ras proto-oncogene in B-cell malignancies. | None |
| Conformational effects of the substitution of Arg for Gly 13 in the ras oncogene-encoded P21 protein. | None |
| Expression of human MKK3 in Drosophila is able to initiate JNK-mediated cell migration, cooperates with oncogenic Ras to trigger tumor invasion, and rescue loss-of-lic induced thorax closure defect. | None |
| Results show that Notch signalling exerts opposing effects in oncogenic Kras-induced MPN; it functions as a potent oncogene in leukaemia cells per se (Kong et al , 2019), but acts as a tumour suppressor gene in non-haematopoietic cells. | None |